SUNHAWK BIO
視航生物醫學股份有限公司
SUNHAWK BIO is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is SHJ002 (Phase 2; active not recruiting, Myopia, Progressive), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| SHJ002 | — | Phase 2; active not recruiting | Myopia, Progressive | Taiwan, United States | 2026-01-23 | Trial registry |
| SHJ002-SJP | — | Phase 2; completed | Corneal Erosion | Taiwan | 2025-08-22 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.